September 18, 2006Archives of Internal Medicine
It Is Time to Stop Comparing Blood Pressure–Lowering Drugs With Placebo—Reply
Key result
The blood pressure-lowering effect of antihypertensive drugs explains most of their clinical efficacy, suggesting that placebo-controlled trials for cardiovascular outcomes should be abandoned.
Population
Patients who recovered from an acute myocardial infarction, with mildly depressed or preserved ejection…
Comparison
Angiotensin-converting enzyme inhibitors and… vs Placebo
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
The author argues that cardiovascular trials evaluating antihypertensive drugs should use active comparators instead of placebo, as blood pressure reduction primarily drives clinical efficacy.
Structured PICO
P
Population
Patients who recovered from an acute myocardial infarction, with mildly depressed or preserved ejection fraction (40%)
I
Intervention
Angiotensin-converting enzyme (ACE) inhibitors (e.g., perindopril) and other blood pressure-lowering drugs
C
Comparator
Placebo
O
Outcome
Left ventricular remodeling and hard cardiovascular outcomes
The author argues that cardiovascular trials evaluating antihypertensive drugs should use active comparators instead of placebo, as blood pressure reduction primarily drives clinical efficacy.
Cite This Study
Roberto Ferrari (2006) conducted a letter in Acute myocardial infarction. Blood pressure-lowering drugs vs. Placebo was evaluated. The blood pressure-lowering effect of antihypertensive drugs explains most of their clinical efficacy, suggesting that placebo-controlled trials for cardiovascular outcomes should be abandoned.